Daniel Ying Wang
Vanderbilt University Medical Center
8 Papers
34 Citations
Daniel Ying Wang is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Melanoma & Immunotherapy. The author has an hindex of 3, co-authored 8 publications. Previous affiliations of Daniel Ying Wang include Baylor College of Medicine & Vanderbilt University.
Chat about Author
Papers
Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma
Rajat Rai,Jennifer L. McQuade,Daniel Ying Wang,John J. Park,K. Nahar,J. A. Sosman,Kathryn E. Beckermann,Lauren E. Haydu,Serigne Lo,Samuel M. Rubinstein,Meredith Ann McKean,S. Matthew,Alexander Guminski,Matteo S. Carlino,Michael Davies,Douglas B. Johnson,Georgina V. Long,Alexander M. Menzies +17 more
15
Activity of targeted therapy after failure of first-line immunotherapy in BRAF-mutant metastatic melanoma.
Cathy Yi Xia,Daniel Ying Wang,Robert Mason,Jessica Smith,Meredith Ann McKean,Serigne Lo,Alexander Guminski,Georgina V. Long,Matteo S. Carlino,Victoria Atkinson,Michael Millward,Jennifer L. McQuade,Rodabe N. Amaria,Douglas B. Johnson,Alexander M. Menzies +14 more
TL;DR: This data indicates that a second line therapy is likely to be beneficial in patients with BRAF-mutant melanoma despite the small number of studies investigating this mode of treatment.
13
MHC-II expression to drive a unique pattern of adaptive resistance to antitumor immunity through receptor checkpoint engagement.
Justin M. Balko,Douglas B. Johnson,Daniel Ying Wang,Paula I. Ericsson-Gonzalez,Mellissa J. Nixon,Roberto Salgado,Violeta Sanchez,Daniel M. Schreeder,Ju Young Kim,Jennifer Bordeaux,Melinda E. Sanders,Randall S. Davis +11 more
TL;DR: To determine the functional effect of MHC-II on tumor cells, the authors generated isogenic M HC-II+ mouse tumors and assessed immune responsiveness and efficacy of checkpoi...
9
Inhibition of CDK4/6 Overcomes Primary Resistance to PD-1 Blockade in Malignant Mesothelioma
Hee Jin Jang,Cynthia Y. Truong,Eric M. Lo,Hudson M. Holmes,Daniela Ramos,Maheshwari Ramineni,Jangsoon Lee,Daniel Ying Wang,Massimo Pietropaolo,Robert T. Ripley,Bryan M. Burt,Hyun-Sung Lee +11 more
TL;DR: In this paper, a novel therapeutic target, CDK4/6, was identified to overcome primary resistance to checkpoint immunotherapy in malignant pleural mesothelioma (MPM) patients.
5
Molecular characterization of immune-related severe adverse events (irSAE).
Justin M. Balko,Rami N. Al-Rohil,Daniel Ying Wang,Yan Liang,Giang T. Ong,Kristi Barker,Margaret L. Compton,Yu Wang,Joseph M. Beechem,Yaomin Xu,Jeffrey A. Sosman,Bret C. Mobley,Chanjuan Shi,Javid Moslehi,Douglas B. Johnson +14 more
TL;DR: Two novel immune checkpoint inhibitors are reported to have shown clinical success in many cancers, but may cause rare irSAE, which has not been previously linked to other types of cancer.
2